Seattle biotech company OncoResponse landed $27M to advance the development and testing of its antibody-based immunotherapy treatments that fight cancer. New funds will support the development of OR502 and OR2805, immunotherapy candidates undergoing testing.
The funds consist of a $13 million grant from the Cancer Prevention and Research Institute of Texas, as well as $14 million from existing investors. The round was led by RiverVest Venture Partners, with participation from ARCH Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, InterVest, and others.